Table 2.
Median expression values (and inter-quartile ranges) of MDR-1, MRP-2 and LRP among study population.
| Parameters | Bone Marrow | Blood | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | MDR-1 | MRP-2 | LRP | N | MDR-1 | MRP-2 | LRP | |||||||||||||
| Med | 25th | 75th | Med | 25th | 75th | Med | 25th | 75th | Med | 25th | 75th | Med | 25th | 75th | Med | 25th | 75th | |||
| AML Classification | ||||||||||||||||||||
| APL (M3); t15:17 | 17 | 0.06 | 0.01 | 0.11 | 0.15 | 0.00 | 0.68 | 3.23 | 0.34 | 15.70 | 14 | 0.06 | 0.03 | 0.20 | 0.02 | 0.00 | 0.13 | 0.71 | 0.29 | 3.94 |
| AML without maturation (M1) | 14 | 0.03 | 0.00 | 0.35 | 0.06 | 0.01 | 0.28 | 0.59 | 0.30 | 2.42 | 13 | 0.07 | 0.03 | 0.86 | 0.33 | 0.01 | 1.45 | 1.73 | 0.37 | 4.43 |
| AML with maturation (M2) | 40 | 0.06 | 0.00 | 0.14 | 0.01 | 0.00 | 0.06 | 0.78 | 0.33 | 4.25 | 38 | 0.12 | 0.00 | 0.25 | 0.03 | 0.00 | 0.11 | 1.68 | 0.67 | 3.69 |
| Others | 11 | 0.00 | 0.00 | 0.05 | 0.01 | 0.00 | 0.07 | 1.04 | 0.29 | 9.90 | 12 | 0.37 | 0.02 | 0.92 | 0.21 | 0.00 | 16.50 | 1.22 | 0.29 | 31.80 |
| AML Classification (Prognostic) | ||||||||||||||||||||
| APL (M3) | 17 | 0.06 | 0.01 | 0.11 | 0.15 | 0.00 | 0.68 | 3.23 | 0.34 | 15.70 | 14 | 0.06 | 0.03 | 0.20 | 0.02 | 0.00 | 0.13 | 0.71 | 0.29 | 3.94 |
| All Others | 61 | 0.04 | 0.00 | 0.13 | 0.01 | 0.00 | 0.07 | 0.75 | 0.32 | 2.56 | 58 | 0.11 | 0.01 | 0.39 | 0.04 | 0.00 | 0.30 | 1.49 | 0.51 | 3.45 |
| Myeloperoxidase Status | ||||||||||||||||||||
| Negative | 13 | 0.05 | 0.02 | 0.09 | 0.15 | 0.03 | 0.67 | 3.82 | 0.63 | 21.90 | 12 | 0.10 | 0.01 | 0.24 | 0.03 | 0.00 | 0.65 | 1.36 | 0.75 | 4.93 |
| Positive | 58 | 0.05 | 0.00 | 0.13 | 0.01 | 0.00 | 0.08 | 0.66 | 0.31 | 2.38 | 55 | 0.09 | 0.01 | 0.30 | 0.04 | 0.00 | 0.26 | 1.22 | 0.30 | 3.39 |
| Sample Type | ||||||||||||||||||||
| Pre-chemotherapy Sample | 32 | 0.04 | 0.00 | 0.08 | 0.04 | 0.00 | 0.31 | 1.33 | 0.30 | 2.42 | 31 | 0.10 | 0.01 | 0.59 | 0.04 | 0.01 | 0.44 | 1.05 | 0.21 | 3.24 |
| Post-chemotherapy Sample | 50 | 0.05 | 0.00 | 0.13 | 0.02 | 0.00 | 0.08 | 0.93 | 0.35 | 5.63 | 46 | 0.10 | 0.01 | 0.26 | 0.04 | 0.00 | 0.27 | 1.73 | 0.70 | 4.04 |
| Remission Status | ||||||||||||||||||||
| Resistant | 32 | 0.05 | 0.00 | 0.14 | 0.01 | 0.00 | 0.09 | 0.70 | 0.25 | 2.35 | 31 | 0.12 | 0.01 | 0.30 | 0.05 | 0.00 | 0.33 | 1.48 | 0.44 | 3.98 |
| Relapse | 15 | 0.00 | 0.00 | 0.08 | 0.01 | 0.00 | 0.06 | 0.34 | 0.24 | 0.69 | 15 | 0.03 | 0.00 | 0.53 | 0.03 | 0.00 | 0.29 | 0.99 | 0.18 | 3.40 |
| Persistent Remission | 35 | 0.04 | 0.00 | 0.12 | 0.04 | 0.00 | 0.59 | 2.64 | 0.44 | 6.54 | 31 | 0.10 | 0.03 | 0.27 | 0.02 | 0.00 | 0.33 | 1.73 | 0.72 | 4.04 |
| Survival Status | ||||||||||||||||||||
| Dead | 37 | 0.01 | 0.00 | 0.08 | 0.01 | 0.00 | 0.07 | 0.48 | 0.26 | 1.60 | 35 | 0.05 | 0.00 | 0.30 | 0.04 | 0.00 | 0.26 | 0.99 | 0.31 | 3.24 |
| Alive | 42 | 0.07 | 0.02 | 0.14 | 0.02 | 0.00 | 0.42 | 2.12 | 0.43 | 5.43 | 39 | 0.12 | 0.03 | 0.59 | 0.03 | 0.00 | 0.28 | 1.53 | 0.70 | 3.90 |